Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial

References

• ParkinDMBrayFFerlayJGlobal cancer statistics, 2002CA Cancer J Clin20055527410815761078
   PubMed Web of Science ®Google Scholar
• DevesaSSBlotWJFraumeniJFJrChanging patterns in the incidence of esophageal and gastric carcinoma in the United StatesCancer19988310204920539827707
   PubMed Web of Science ®Google Scholar
• EnzingerPCMayerRJEsophageal cancerN Engl J Med2003349232241225214657432
   PubMed Web of Science ®Google Scholar
• HerskovicAMartzKal-SarrafMCombined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagusN Engl J Med199232624159315981584260
   PubMed Web of Science ®Google Scholar
• CooperJSGuoMDHerskovicAChemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective radomized trial (RTOG85–01). Radiation Therapy Oncology GroupJ Am Med Assoc19992811716231627
   PubMed Web of Science ®Google Scholar
• Al-SarrafMMartzKHerskovicAProgress report of combined chemotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup studyJ Clin Oncol19971512772848996153
   PubMed Web of Science ®Google Scholar
• LageACrombetTGonzalezGTargeting epidermal growth factor receptor signaling: early results and future trends in oncologyAnn Med200335532733612952019
   PubMed Web of Science ®Google Scholar
• DobashiYStrenDFMembrane-anchored forms of EGF stimulate focus formation and intercellular communicationOncogene19916115111591861865
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaAFLEX Study TeamCetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trialLancet200937396741525153119410716
   PubMed Web of Science ®Google Scholar
• CunninghamDHumbletYSienaSCetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med2004351433734515269313
   PubMed Web of Science ®Google Scholar
• VermorkenJBMesiaRRiveraFPlatinum-based chemotherapy plus cetuximab in head and neck cancerN Engl J Med2008359111116112718784101
   PubMed Web of Science ®Google Scholar
• Crombet-RamosTRakJPerezRAntiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibodyInt J Cancer2002101656757512237899
   PubMed Web of Science ®Google Scholar
• AkashiYOkamotoIIwasaTEnhancement of the antitumor activity of ionizing radiation by Nimotuzumab, a humanized monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor statusBr J Cancer200898474975518253126
   PubMed Web of Science ®Google Scholar
• ZhaoLHeLRXiMNimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP–3J Transl Med20121024923232108
   PubMed Web of Science ®Google Scholar
• RodríguezMORiveroTCBaiRCNimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neckCancer Biology Therapy20109534334920448462
   PubMed Web of Science ®Google Scholar
• RamakrishnanMSEswaraiahACrombetTNimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originMAbs200911414820046573
   PubMed Web of Science ®Google Scholar
• CrombetTOsorioMCruzTUse of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patientsJ Clin Oncol20042291646165415117987
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events v3.0 (CTCAE)2006 Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfAccessed September 25, 2013
   Google Scholar
• EisenhauerETherassePBogaertsJNew response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)Euro J Cancer2009452228247
   PubMed Web of Science ®Google Scholar
• GotohMTakiuchiHKawabeSEpidermal Growth Factor Receptor is a Possible Predictor of Sensitivity to Chemoradiotherapy in the Primary Lesion of Esophageal Squamous Cell CarcinomaJpn J Clin Oncol200737965265717940077
   PubMed Web of Science ®Google Scholar
• SafranHDipetrilloTAkermanPPhase I/II study of transtuzumab paclitaxel, cisplatin and radiation for locally advanced., HER 2 overexpressing esophageal adenocarcinomaInt J Radiat Oncol Biol Phys200767240540917097832
   PubMed Web of Science ®Google Scholar
• HanJZhuWTuCClinical study of concurrent chemoradiotherapy or radiotherapy alone for esophageal cancer patients with positive lymph node metastasisTumori2012981606522495703
   PubMed Web of Science ®Google Scholar
• SmithTJRyanLMDouglassHOJrCombined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperatve Oncology GroupInt J Radiat Oncol Biol Phys19984222692769788404
   PubMed Web of Science ®Google Scholar
• KuwanoHKatoHMiyazakiTGenetic alterations in esophageal cancerSurg Today200535171815622457
   PubMed Web of Science ®Google Scholar
• SheridanMTO’DwyerTSeymourCBPotential indicators of radiosensitivity in squamous cell carcinoma of the head and neckRadiat Oncol Investig199754180186
   PubMedGoogle Scholar
• MasonKAKomakiRCoxJDBiology-based combined –modality radiotherapy: workshop reportInt J Radiat Oncol Biol Phys20015041079108911429236
   PubMed Web of Science ®Google Scholar
• BarkerFGIISimmonsMLChangSMEGFR overexpression and radiation response in glioblastoma multiformeInt J Radiat Oncol Biol Phys200151241041811567815
   PubMed Web of Science ®Google Scholar
• AkimotoTMolecular basis and clinical results of radiation therapy combined with molecular targeted therapyNippon Rinsho2010681025103420535951
   PubMedGoogle Scholar
• EnzingerPYockTSuhWPhase II cisplatin, irrinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition)J Clin Oncol200624Suppl 184064
   Google Scholar
• DawsonSJMichaelMBiagiJA phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancerInvest New Drugs200725212312917053988
   PubMed Web of Science ®Google Scholar
• SunpaweravongPSunpaweravongSSangthawanDCombination of gefitinib, cisplatin and 5-Fu chemotherapy, and radiation therapy (RT) in newly diagnosed patients with esophageal carcinoma2007 ASCO Annual meeting Proceedings (Post-Meeting Edition)J Clin Oncol2007218S4605
   Google Scholar
• PandeAULverRVRaniAEpidermal growth factor receptor-directed therapy in esophageal cancerOncology2007735–628128918477853
   PubMed Web of Science ®Google Scholar
• SafranHSuntharalingamMDipetrilloTCetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicityInt J Radiat Oncol Biol Phys200870239139517980508
   PubMed Web of Science ®Google Scholar
• De VitaFOrdituraMInnocenteRInduction primary CT with Folfox-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC): Analysis of preliminary data from B152 Trial2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition)J Clin Oncol20082615S15524
   Google Scholar
• RodriguezCAdelsteinDRybickiLA phase II trial of perioperative concurrent chemoradiotherapy (CCRT) and gefitinib (G) in locally advanced esophagus (E) and gastroesophageal junction (GEJ) cancer2008 ASCO Annual Meeting proceedings (Post-Meeting Edition)J Clin Oncol20082615S4547
   Google Scholar
• JavleMPandeALyerRPilot study of gefitinib, oxaliplatin and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical responseAm J Clin Oncol200831432933418845990
   PubMed Web of Science ®Google Scholar
• RuhstallerTPlessMSchullerJSwiss Group for Clinical Cancer Research (Schweizerische Arbeitsgemeinschaft fur Klinische Krebsforschung) Cetuximab in combination with chemoradiotherapy prior to surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase I B/II trial (SAKK 75/06)Presented in part at the 45th Annual Meeting of the American Society of Clinical OncologyMay 29-June 2, 2009Orlando, FLJ Clin Oncol201129662663121205757
   PubMedGoogle Scholar
• IlsonDBainsMRizkNPhase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (RT) in esophageal adenocarcinoma: preliminary safety analysis2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition)J Clin Oncol20092715S4573
   Google Scholar
• AgrawalaAHannaNMcCollumAPreoperative cetuximab and radiation (XRT) for patients with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition)J Clin Oncol20092715S4557
   Google Scholar
• LiGHuWWangJPhase II study of concurrent chemoradiation in combination with erlotinib for local advanced esophageal carcinomaPresent in part at the 44th ASCO Annual MeetingMay 30–June, 2008Chicago, ILInt J Radiation Oncology Biol Phys201028514071412
   Google Scholar
• BendellJCMeluchAPeytonJA phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancerClin Adv Hematol Oncol201210743043722895283
   PubMedGoogle Scholar
• CrosbyTHutCFalkSChemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trialLancet Oncol20131462763723623280
   PubMed Web of Science ®Google Scholar
• IyerRChhatralaRShefterTErlotinib and radiation therapy for elderly patients with esophageal cancer- clinical and correlative results from a prospective multicentre phase 2 trialOncology201385535823860007
   PubMed Web of Science ®Google Scholar
• ZhaiYHuiZWangJConcurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot studyDis Esoph201326503509
   PubMed Web of Science ®Google Scholar